Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › idelalisib

idelalisib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of idelalisib

11 trials tracked of idelalisib: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 247 citations.

11Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 7 Phase 1 2
  1. Phase 3 Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) Completed · 247 cited
  2. Phase 3 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Completed
  3. Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed
  4. Phase 2 A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Completed
  5. Phase 2 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas Completed
  6. Phase 2 Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Completed
Show 5 more trials
  1. Phase 2 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Completed
  2. Phase 2 Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma Completed
  3. Phase 2 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Completed
  4. Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) Completed
  5. Phase 1 Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
Rheumatology Cohort
Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis 15,000 Cases Found: Which Drugs Harm Your Lungs?
A retrospective pharmacovigilance investigation analyzed 15,374 cases in FAERS and Vigibase databases to identify drug-induced eosinophilic …
A massive data review reveals which medicines might silently damage your lungs.
Frontiers Apr 22, 2026
Phase 2 trial explores idelalisib plus ofatumumab in untreated CLL/SLL requiring treatment
Hematology Phase II
Phase 2 trial explores idelalisib plus ofatumumab in untreated CLL/SLL requiring treatment Can two drugs together help people with untreated blood cancer?
A phase 2 interventional trial evaluated idelalisib plus ofatumumab in 27 previously untreated CLL/SLL patients requiring therapy.
For people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment, researchers tested a combinat…
CT.gov Mar 30, 2026